CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.12% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money

Trade Stoke Therapeutics, Inc. - STOK CFD

9.30
0.96%
Market Trading Hours* (UTC) Opens on Tuesday at 14:30

Tue - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
Trading сonditions
Spread 0.11
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.023346 %
Charges from full value of position ($-0.23)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
-0.023346%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.001124 %
Charges from full value of position ($0.01)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
0.001124%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 50.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 9.39
Open 9.38
1-Year Change 89.11%
Day's Range 9.3 - 9.6
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jan 16, 2025 9.39 -0.03 -0.32% 9.42 9.53 8.92
Jan 15, 2025 9.43 0.72 8.27% 8.71 9.72 8.71
Jan 14, 2025 8.61 -0.23 -2.60% 8.84 9.05 8.37
Jan 13, 2025 8.86 0.09 1.03% 8.77 8.94 8.50
Jan 10, 2025 8.95 0.21 2.40% 8.74 9.00 8.73
Jan 8, 2025 8.90 -0.54 -5.72% 9.44 9.44 8.70
Jan 7, 2025 9.24 -0.58 -5.91% 9.82 10.43 8.82
Jan 6, 2025 10.98 -0.38 -3.35% 11.36 11.55 10.93
Jan 3, 2025 11.44 0.29 2.60% 11.15 11.64 11.13
Jan 2, 2025 11.23 0.26 2.37% 10.97 11.59 10.82
Dec 31, 2024 11.00 0.22 2.04% 10.78 11.03 10.71
Dec 30, 2024 10.75 -0.06 -0.56% 10.81 11.02 10.46
Dec 27, 2024 11.00 -0.06 -0.54% 11.06 11.43 10.87
Dec 26, 2024 11.18 0.18 1.64% 11.00 11.42 10.97
Dec 24, 2024 11.28 0.06 0.53% 11.22 11.46 11.08
Dec 23, 2024 11.54 0.00 0.00% 11.54 11.72 11.23
Dec 20, 2024 11.62 0.85 7.89% 10.77 11.79 10.77
Dec 19, 2024 11.23 0.16 1.45% 11.07 11.28 10.56
Dec 18, 2024 11.04 -0.92 -7.69% 11.96 11.99 10.74
Dec 17, 2024 12.04 -0.01 -0.08% 12.05 12.41 11.94

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
Leverage
2:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Stoke Therapeutics, Inc. Company profile

About Stoke Therapeutics Inc

Stoke Therapeutics, Inc. is a biotechnology company. It focuses to treat the underlying causes of severe genetic diseases by upregulating protein expression. It is developing antisense oligonucleotide (ASO) medicines that target ribonucleic acid (RNA) and modulate precursor-messenger RNA (pre-mRNA) splicing to upregulate protein expression where needed and with appropriate specificity to near normal levels. It focuses to develop the precision medicine platform to target the underlying cause of a spectrum of genetic diseases in which the patient has healthy copy of a gene and mutated copy that fails to produce a protein essential to health. It utilizes its technology platform, Targeted Augmentation of Nuclear Gene Output (TANGO) to design ASOs to upregulate the expression of protein by individual genes in a patient. Its product candidate, STK-001, is offered to treat Dravet syndrome. Its research platform is designed to address protein deficiency.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Stoke Therapeutics Inc revenues was not reported. Net loss increased 64% to $85.8M. Higher net loss reflects Research and development - Balancing val increase of 58% to $48M (expense), Stock-based Compensation in SGA increase from $3.9M to $10.2M (expense), General and administrative - Balancing increase of 28% to $21.7M (expense).

Industry: Biotechnology & Medical Research (NEC)

45 Wiggins Avenue
BEDFORD
MASSACHUSETTS 01730
US

People also watch

BTC/USD

104,515.35 Price
+4.320% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 50.00

Gold

2,703.08 Price
-0.430% 1D Chg, %
Long position overnight fee 0.0056%
Short position overnight fee -0.0138%
Overnight fee time 22:00 (UTC)
Spread 0.60

ETH/USD

3,475.00 Price
+4.570% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

XRP/USD

3.29 Price
-0.550% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 0.01639

Still looking for a broker you can trust?

Join the 660,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading